Javascript must be enabled to continue!
The deductibility of Sarbanes-Oxley costs incurred by Australasian companies
View through CrossRef
Purpose– This paper aims to examine the nature of Sarbanes-Oxley (SOX) costs incurred by subsidiaries of USA parent companies, and considers whether any value flows to non-USA subsidiaries. Deductibility is analysed under both the general deductibility provisions and the transfer pricing regimes of Australia and New Zealand (NZ). Reference is also made to the Organisation for Economic Cooperation and Development (OECD) transfer pricing guidelines and the US transfer pricing regulations. Australasian and New Zealand subsidiaries of US parent companies frequently incur costs related to their parent’s regulatory reporting requirements under the Sarbanes-Oxley Act of 2002. Tax authorities, generally, view these costs as “shareholder activities”, i.e. activities performed for the benefit of the parent only. As such, they are considered non-deductible to the subsidiaries of USA parents because an independent party dealing at arm’s length would not pay to receive similar services. We consider circumstances in which some costs may be deductible.Design/methodology/approach– Legal analysis.Findings– We conclude that there can be circumstances where these so-called shareholder activities do provide value to subsidiaries and, accordingly, may (or should) be deductible in the local jurisdiction.Research limitations/implications– This analysis is limited to a consideration of Australian, NZ, OECD and US sources.Practical implications– This paper provides an analysis of the deductibility of a type of expenditure commonly encountered by subsidiaries of US parent companies.Originality/value– Limited research is available that deals with this issue. In most cases, only general statements on deductibility of similar types of expenditure are available to taxpayers.
Title: The deductibility of Sarbanes-Oxley costs incurred by Australasian companies
Description:
Purpose– This paper aims to examine the nature of Sarbanes-Oxley (SOX) costs incurred by subsidiaries of USA parent companies, and considers whether any value flows to non-USA subsidiaries.
Deductibility is analysed under both the general deductibility provisions and the transfer pricing regimes of Australia and New Zealand (NZ).
Reference is also made to the Organisation for Economic Cooperation and Development (OECD) transfer pricing guidelines and the US transfer pricing regulations.
Australasian and New Zealand subsidiaries of US parent companies frequently incur costs related to their parent’s regulatory reporting requirements under the Sarbanes-Oxley Act of 2002.
Tax authorities, generally, view these costs as “shareholder activities”, i.
e.
activities performed for the benefit of the parent only.
As such, they are considered non-deductible to the subsidiaries of USA parents because an independent party dealing at arm’s length would not pay to receive similar services.
We consider circumstances in which some costs may be deductible.
Design/methodology/approach– Legal analysis.
Findings– We conclude that there can be circumstances where these so-called shareholder activities do provide value to subsidiaries and, accordingly, may (or should) be deductible in the local jurisdiction.
Research limitations/implications– This analysis is limited to a consideration of Australian, NZ, OECD and US sources.
Practical implications– This paper provides an analysis of the deductibility of a type of expenditure commonly encountered by subsidiaries of US parent companies.
Originality/value– Limited research is available that deals with this issue.
In most cases, only general statements on deductibility of similar types of expenditure are available to taxpayers.
Related Results
Corporate Governance, Sarbanes-Oxley, and Small-Cap Firm Performance
Corporate Governance, Sarbanes-Oxley, and Small-Cap Firm Performance
The recent debate on the onerous costs of compliance with the Sarbanes-Oxley Act has primarily focused on small firms. We study the effects of Sarbanes-Oxley compliance on small fi...
From Enron to Worldcom and Beyond: Life and Crime after Sarbanes-Oxley
From Enron to Worldcom and Beyond: Life and Crime after Sarbanes-Oxley
In roughly two years since the corporate meltdown began, federal and state regulators have initiated criminal fraud investigations involving dozens of corporations, including Enron...
Method of evaluating and diagnosing costs for event management
Method of evaluating and diagnosing costs for event management
The article develops a method of evaluating and diagnosing costs for event management in the form of a matrix that takes into account the directions of managing event processes of ...
Health‐care Nonprofits: Enhancing Governance and Public Trust
Health‐care Nonprofits: Enhancing Governance and Public Trust
ABSTRACTNonprofits are a major part of the U.S. economy and they are not immune from corporate malfeasance controversies. Even Congress has expressed concern about the crisis in no...
ปัจจัยที่มีผลกระทบต่อความเสี่ยงจากการตรวจไม่พบข้อผิดพลาดในการสอบบัญชีภายใต้มาตรการสับเปลี่ยนผู้สอบบัญชีของ Sarbanes-Oxley Act ในประเทศไทย
ปัจจัยที่มีผลกระทบต่อความเสี่ยงจากการตรวจไม่พบข้อผิดพลาดในการสอบบัญชีภายใต้มาตรการสับเปลี่ยนผู้สอบบัญชีของ Sarbanes-Oxley Act ในประเทศไทย
วิทยานิพนธ์นี้มีวัตถุประสงค์ คือ เพื่อศึกษาถึงระดับความเสี่ยงจากการตรวจไม่พบข้อผิดพลาดในงานสอบบัญชี ปัจจัยที่คาดว่าจะมีผลกระทบต่อความเสี่ยงจากการตรวจไม่พบข้อผิดพลาด ทั้งมุมมองของผู...
Healthcare Utilization and Imputed Costs of Acute Myeloid Leukemia Patients By FLT3 Status and Early Midostaurin Use at a Comprehensive Cancer Center
Healthcare Utilization and Imputed Costs of Acute Myeloid Leukemia Patients By FLT3 Status and Early Midostaurin Use at a Comprehensive Cancer Center
Abstract
INTRODUCTION: Mutation of FLT3, a tyrosine kinase receptor, is one of the most common molecular alterations in AML. In 2017, the FDA approved midostaurin fo...
Laboratory Costs in the Context of Disease
Laboratory Costs in the Context of Disease
Abstract
Background: To determine the contribution of laboratory costs to the overall costs of managing hospital patients with different diseases, we studied the cos...
Technical Analysis in Financial Markets
Technical Analysis in Financial Markets
The efficient markets hypothesis states that in highly competitive and developed markets it is impossible to derive a trading strategy that can generate persistent excess profits a...

